黄连解毒汤对急性冠脉综合征患者VEGF及hs-CRP、NO的影响

目的 观察黄连解毒汤对急性冠脉综合征（ACS）患者冠脉介入术（PCI）术后血管内皮生长因子（VEGF）、一氧化氮（N0）以及超敏C反应蛋白（hs-CRP）的影响.方法 选取将80例临床确诊为ACS患者随机分为对照组和黄连解毒汤治疗组,两组各40例.对照组采用西医常规方法治疗,治疗组在此基础上加用黄连解毒汤治疗,两组疗程均为30 d.结果 治疗后两组心绞痛发作频率和持续时间均下降（P＜0.01）,组间比较,治疗组改善情况优于对照组（P＜0.01）.治疗后治疗组有效率为77.50％,明显高于对照组的47.50％ （P＜0.01）;治疗组治疗后血清VEGF、NO和hs-CRP含量与对照组比较,差异均有统计学意义（P＜0.01）.治疗后治疗组在躯体活动受限程度、心绞痛稳定状态、心绞痛发作情况、治疗满意程度优于对照组（P＜ 0.01）.在疾病认识程度上两组差异无统计学意义（P＞0.05）.结论 黄连解毒汤可提高ACS患者PCI术后VEGF、NO水平以及降低hs-CRP水平,促进冠状动脉侧支循环的建立,改善心肌缺氧状态,抑制PCI术后炎性反应.

Effect of Huanglianjiedu Decoction on Serum VEGF,NO and hs-CRP in Acute Coronary Syndrome Patients

Objective：To investigate the effect of Huanglianjiedu Decoction on serum vascular endothelial growth factor（VEGF）,nitric oxide （NO） and C-reactive protein （hs-CRP） in acute coronary syndrome patients after PCI.Methods：80 cases of ACS were randomized into two groups includin 40 cases in treatment group and 40 in control group.Besides that the routine therapies were used in 2 groups,the treatment group was added the Huanglianjiedu Decoction.The treatment periods in 2 groups were lasted for 30 days.Results：After treatment,the frequency and the duration of the angina attack in 2 groups were improved significantly （P〈 0.01）.The improvement in the treatment group was superior to that in the control group（P〈 0.05）.The total effective rate of the treatment group was higher obviously than that of the control group （P〈 0.01）.There were statistical differences after treatment between 2 groups in the VEGF,NO and hs-CRP （P〈 0.01）.The effects of treatment group were better than those of control group in the physical activities limitation,the angina stability degree,the angina attack and the treatment satisfactory degree（P〈 0.05）.However,there was no remarkable difference between 2 groups in the recognition for the acute coronary syndrome （P〉 0.05）.Conclusion：Huanglianjiedu Decoction could elevate serum VEGF,NO and reduce hs-CRP levels after PCI of ACS sufferers.h can improve the oxygen supply in coronary heart disease and inhibit post-operative inflammation diseases.